| Literature DB >> 22021722 |
Gregorio Tugnoli1, Eleonora Giorgini, Andrea Biscardi, Silvia Villani, Nicola Clemente, Gianluca Senatore, Filippo Filicori, Nicola Antonacci, Franco Baldoni, Carlo De Werra, Salomone Di Saverio.
Abstract
BACKGROUND: Case control studies that randomly assign patients with diagnosis of acute appendicitis to either surgical or non-surgical treatment yield a relapse rate of approximately 14% at one year. It would be useful to know the relapse rate of patients who have, instead, been selected for a given treatment based on a thorough clinical evaluation, including physical examination and laboratory results (Alvarado Score) as well as radiological exams if needed or deemed helpful. If this clinical evaluation is useful, the investigators would expect patient selection to be better than chance, and relapse rate to be lower than 14%. Once the investigators have established the utility of this evaluation, the investigators can begin to identify those components that have predictive value (such as blood analysis, or US/CT findings). This is the first step toward developing an accurate diagnostic-therapeutic algorithm which will avoid risks and costs of needless surgery. METHODS/Entities:
Year: 2011 PMID: 22021722 PMCID: PMC3191386 DOI: 10.1136/bmjopen-2010-000006
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Non-operative treatment for acute appendicitis: patient outcomes and follow-up in a single-cohort prospective observational study. Flow diagram of the study according to CONSORT 2010.
Figure 2CONSORT 2010 flow diagram.
STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of case–control studies
| Item # | Recommendation | Reported on page # | |
| 1 | 2–3 | ||
| 2–3 | |||
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | 5–10 |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | 12–14 |
| Study design | 4 | Present key elements of study design early in the paper | 14 |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | 10–11/14–16 |
| Participants | 6 | 15 | |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | 10–11/12–14 |
| Data sources/measurement | 8 | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | 11–12 |
| Bias | 9 | Describe any efforts to address potential sources of bias | 4 |
| Study size | 10 | Explain how the study size was arrived at | 14 |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | 11–12 |
| Statistical methods | 12 | 11–12 | |
| 11–12 | |||
| 11–12 | |||
| 11–12 | |||
| 11–12 | |||
| Results | |||
| Participants | 13 | (a) Report numbers of individuals at each stage of study—for example, numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | Not yet applicable |
| (b) Give reasons for non-participation at each stage | Not yet applicable | ||
| (c) Consider use of a flow diagram | Not yet applicable | ||
| Descriptive data | 14 | (a) Give characteristics of study participants (eg, demographic, clinical, social) and information on exposures and potential confounders | Not yet applicable |
| (b) Indicate number of participants with missing data for each variable of interest | Not yet applicable | ||
| Outcome data | 15 | Report numbers in each exposure category, or summary measures of exposure | Not yet applicable |
| Main results | 16 | Not yet applicable | |
| Not yet applicable | |||
| Not yet applicable | |||
| Other analyses | 17 | Report other analyses done—for example, analyses of subgroups and interactions, and sensitivity analyses | Not yet applicable |
| Discussion | Not yet applicable | ||
| Key results | 18 | Summarise key results with reference to study objectives | Not yet applicable |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | Not yet applicable |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | Not yet applicable |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | Not yet applicable |
| Other information | Not yet applicable | ||
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | 16 |
Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.
An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org/.